Remove 2023 Remove Health Services Administration Remove Telemedicine
article thumbnail

DEA Extends COVID-19 Telemedicine Flexibilities for Prescribing Controlled Medications for 6 Months

HIT Consultant

For any practitioner-patient telemedicine relationships that have been or will be established up to November 11, 2023, the full set of telemedicine flexibilities regarding the prescription of controlled medications established during the COVID-19 PHE will be extended for one year – through November 11, 2024.

article thumbnail

DEA & SAMHSA Issue Temporary Rule Extending COVID-19 Telemedicine Flexibilities for Controlled Substances Prescribing Beyond the Termination of COVID-19 PHE

Hall Render

Notably, the Temporary Rule, which can be accessed here , extends the COVID-19 PHE telemedicine flexibilities (hereinafter, “telemedicine flexibilities”) for six months following the end of the PHE (through November 11, 2023).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Tele-Prescribing Flexibilities Extended Again in Second Temporary Rule

Healthcare Law Blog

Under the Second Temporary Rule, practitioners may continue to prescribe schedule II-V controlled medications via telemedicine for new and existing patients without conducting a prior in-person medical evaluation through 2024.

article thumbnail

DEA officially extends remote EPCS flexibilities for 6 months

Healthcare IT News - Telehealth

Department of Health and Human Services said it would temporarily extend telemedicine flexibilities for the prescription of certain controlled medications granted under the COVID-19 Public Health Emergency, which is set to expire on May 11.

article thumbnail

The Wait is Over. Or Is It? DEA’s Proposed Rules Around Telemedicine Prescribing: Initial Impressions and Key Takeaways

Health Law Advisor

The proposed rules are more restrictive than the DEA emergency waivers under which providers conducted telemedicine prescribing for the last three years, but are less restrictive in comparison to the pre-PHE regulations applicable to telemedicine prescribing of controlled substances under the federal Controlled Substances Act (“CSA”).

article thumbnail

Five Opportunities to Use the Law to Address Persistent OUD Treatment Gaps 

Bill of Health

The nation’s experience with COVID-19 demonstrated the need for increased telemedicine options for the treatment of substance use, especially in suburban and rural areas where health provider closures may severely limit access to care. Code § 1701 et seq.

article thumbnail

DEA Chopping Block: DATA-Waiver Requirement

Healthcare Law Today

On January 12, 2023, the Drug Enforcement Administration (DEA) confirmed in a letter to registrants that the Consolidated Appropriations Act of 2023 (P.L. On January 12, 2023, the Drug Enforcement Administration (DEA) confirmed in a letter to registrants that the Consolidated Appropriations Act of 2023 (P.L.

COVID-19 114